search icon
search icon
Flag Arrow Down
Română
Română
Magyar
Magyar
English
English
Français
Français
Deutsch
Deutsch
Italiano
Italiano
Español
Español
Русский
Русский
日本語
日本語
中国人
中国人

Change Language

arrow down
  • Română
    Română
  • Magyar
    Magyar
  • English
    English
  • Français
    Français
  • Deutsch
    Deutsch
  • Italiano
    Italiano
  • Español
    Español
  • Русский
    Русский
  • 日本語
    日本語
  • 中国人
    中国人
Sections
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
About Us
Contact
Privacy policy
Terms and conditions
Quickly scroll through news digests and see how they are covered in different publications!
  • News
  • Exclusive
    • INSCOP Surveys
    • Podcast
    • EU
    • Diaspora
    • Republic of Moldova
    • Politics
    • Economy
    • Current Affairs
    • International
    • Sport
    • Health
    • Education
    • IT&C knowledge
    • Arts & Lifestyle
    • Opinions
    • Elections 2025
    • Environment
151 new news items in the last 24 hours
  1. Home
  2. Attualità

An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.

Adrian Rusu
whatsapp
facebook
linkedin
x
copy-link copy-link
20 August 2026, 05:37
main event image
International
Foto shutterstock.com/ro
google-preference

Always see our news on Google

Moderna and Merck have announced promising results for an experimental cancer vaccine aimed at patients with melanoma. The phase 3 study included over 1,100 patients with advanced-stage melanoma who were treated with a personalized vaccine, intismeran autogene, along with the immunotherapy Keytruda.


Preliminary results suggest that this combination significantly prolonged the period without disease recurrence and reduced the risk of metastases. Unlike traditional vaccines, intismeran is personalized for each patient, based on the analysis of their tumor. Although the results are promising, the study is not yet complete, and the companies continue to monitor patients to assess overall survival. Moderna's shares rose significantly in response to the announcement, highlighting the high expectations related to messenger RNA technology in oncology. The vaccine is also being tested for other types of cancer, which could open new opportunities in cancer treatments.

Sources

sursa imagine
Spotmedia
Un vaccin anti-cancer dă rezultate promițătoare în melanom. A redus riscul ca boala să revină
sursa imagine
News.ro
Un vaccin anti-cancer al Moderna şi Merck dă rezultate promiţătoare; Acţiunile Moderna au urcat cu peste 120%

Latest News

07:53

Democrats officially prevail in Alaska following Mary Peltola’s victory, expanding their Senate majority to 56 seats versus 44

07:39

Raed Arafat explains why no RO-Alert message was issued for the earthquake: “I am convinced that if any RO-Alert message had been sent at night, we would have received comments”

07:32

Men's handball: CSM Bucharest pulled off a surprise in France against Chambery

07:27

We’ve been using someone else’s resources, but that no longer works: The end of free money — How Romania is preparing for the European budget in which nothing will be received without reforms

07:16

The Government wants to assume responsibility, by March 15, for the bills concerning the restructuring of state-owned companies and administrative reorganization

See more news

NEWS ON THE SAME TOPICS

event image
Health
Moderna and Merck announce promising results for the personalized vaccine against melanoma recurrence
event image
International
Russia will use the CaTeVac vaccine from 2027 to treat sarcomas
event image
Health
The U.S. Food and Drug Administration has approved a drug that doubles the survival rate of patients with advanced pancreatic cancer.
event image
Health
The pharmaceutical group Minapharm will develop a candidate vaccine against the Bundibugyo Ebola strain, with funding of 16.5 million dollars.
event image
Health
Alexandru Rogobete proposes expanding genetic testing to six types of cancer, with reimbursement expected from January 1, 2027
event image
EU
The EU–Africa Partnership is providing more than €64 million to fund five networks aimed at speeding up clinical trials during epidemics
app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview app preview
experimental vaccine modern Merck

Editor’s Recommendations

main event image
Current Affairs
56 minutes ago

Magnitude 5.7 earthquake in Vrancea: Two people were injured, while six others were taken to hospital with panic attacks / 9 calls to 112 were recorded in Galați

Sources
imagine sursa
imagine sursa
imagine sursa
imagine sursa
imagine sursa
+5
main event image
Opinions
48 minutes ago
Editorials and opinions

We’ve been using someone else’s resources, but that no longer works: The end of free money — How Romania is preparing for the European budget in which nothing will be received without reforms

main event image
Exclusive
Yesterday 14:45

ANALYSIS Brexit without profit: London seeks reconciliation with the EU

app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview
app store badge google play badge
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
  • About Us
  • Contact
Privacy policy
Cookies Policy
Terms and conditions
Open source licenses
All rights reserved Strategic Media Team SRL

Technology in partnership with

anpc-sal anpc-sol